Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:DARA

(DARA) (DARA) Stock Price, News & Analysis

(DARA) logo

About (DARA) Stock (NASDAQ:DARA)

Key Stats

Today's Range
N/A
50-Day Range
$0.32
$0.33
52-Week Range
N/A
Volume
13,850 shs
Average Volume
118,843 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

DARA BioSciences Inc is specialty pharmaceutical company based in the United States. The Company’s primary focus is on the commercialization of oncology treatment and oncology supportive care pharmaceutical products, including Soltamox, an oral solution of tamoxifen citrate; cancer support therapeutics, including Gelclair, indicated for the treatment of oral mucositis and Bionect, for the management of irritation of the skin as well as first and second degree burns, and Three Mission Pharmacal products, including Ferralet 90 (for anemia), Binosto (alendronate sodium effervescent tablet indicated for the treatment of osteoporosis) and Aquoral (for cancer related dry mouth). The Company has a clinical development asset, KRN5500, which is a Phase II product candidate targeted for treating cancer patients with painful treatment-refractory chronic chemotherapy induced peripheral neuropathy. The Company is a subsidiary of Midatech Pharma Plc.

Receive DARA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (DARA) and its competitors with MarketBeat's FREE daily newsletter.

DARA Stock News Headlines

Dara Khosrowshahi
The only candlestick pattern worth a darn
It’s widely known that 80% of daily market action is driven by Wall Street algorithms… Now, most people think of the algorithms are “bad” When in reality, they are neither good nor bad… They are simply programmed to buy and sell certain stocks over and over again… But here is the thing… They are predictable… They typically buy the same stocks at the same levels over and over again…
Wanted: more bosses on the shop floor
See More Headlines

DARA Stock Analysis - Frequently Asked Questions

(DARA) (NASDAQ:DARA) posted its quarterly earnings data on Monday, November, 2nd. The specialty pharmaceutical company reported ($0.14) earnings per share for the quarter, hitting the consensus estimate of ($0.14). The specialty pharmaceutical company had revenue of $1.18 million for the quarter, compared to analyst estimates of $0.83 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that (DARA) investors own include Castleton Technology (CTP), Richland Resources Ltd (RLD.L) (RLD), Thor Energy (THR), Global Invacom Group (GINV), Legendary Investments (LEG), iPass (IPAS) and Aeterna Zentaris (AEZS).

Company Calendar

Last Earnings
11/02/2015
Today
11/17/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:DARA
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:DARA) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners